Publication & Citation Trends
Publications
43 total
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia. PDF
Cited by 10
OpenAlex
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
Cited by 8
OpenAlex
PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US PDF
Cited by 3
OpenAlex
Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)
Cited by 1
OpenAlex
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care PDF
Cited by 9
OpenAlex
Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers PDF
Cited by 9
OpenAlex
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA
Cited by 4
OpenAlex
Randomized Clinical Trial (RCT) Representativeness and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated in the Real World (RW): Comparison of ASPIRE, TOURMALINE MM1, POLLUX, AND ELOQUENT-2 RCTS
Cited by 3
OpenAlex
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
Cited by 8
OpenAlex
Research Topics
Multiple Myeloma Research and Treatments
(18)
Protein Degradation and Inhibitors
(10)
Cancer Treatment and Pharmacology
(8)
Acute Myeloid Leukemia Research
(7)
Colorectal Cancer Treatments and Studies
(7)
Affiliations
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Wexner Medical Center
AmerisourceBergen (United States)
Ascendis Pharma (Denmark)
Florida Cancer Specialists & Research Institute